公开(公告)号：US20240425820A1

公开(公告)日：2024-12-26

申请号：US18682782

申请日：2022-08-11

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER

IPC: C12N5/071 ,  A61K35/44 ,  C12N5/074 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86 ,  C12N15/90

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells. In some embodiments, the engineered cells comprise increased expression of CD46 and CD59.

公开(公告)号：US20230272429A1

公开(公告)日：2023-08-31

申请号：US17792121

申请日：2021-01-12

Applicant: Sana Biotechnology, Inc.

Inventor： William DOWDLE ,  Andrew MAY ,  Sonja SCHREPFER

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/11 ,  A61K35/545

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/11 ,  C12N15/111 ,  A61K35/545 ,  C12N2310/20 ,  C12N2800/80

Abstract: Provided herein are cells with a gene modification of an ABO gene, RHD gene, and/or FUT1 gene. In some embodiments, the cells express reduced levels of a MHC I antigen and/or a MHC II antigen. In some instances, the cells are also hypoimmunogenic cells.

公开(公告)号：US20230025289A1

公开(公告)日：2023-01-26

申请号：US17637789

申请日：2020-08-24

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER ,  Steve HARR

IPC: A61K35/545 ,  A61K38/17 ,  A61P37/06

Abstract: Disclosed herein are cells including cells expressing CD24 and related methods of their use and generation. In some embodiments, the cells disclosed herein do not express one or more MHC I and/or MHC II human leukocyte antigens. In some embodiments, the cells are hypoimmunogenic.

公开(公告)号：US20240358761A1

公开(公告)日：2024-10-31

申请号：US18682798

申请日：2022-08-11

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER

IPC: A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/00 ,  A61K45/06 ,  C07K14/705 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86 ,  C12N15/90 ,  G01N33/68

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  C07K14/70596 ,  C12N9/22 ,  C12N15/111 ,  C12N15/86 ,  C12N15/907 ,  G01N33/6854 ,  A61K2239/25 ,  A61K2239/38 ,  C12N2310/20 ,  C12N2740/15043 ,  G01N2333/70539 ,  G01N2800/24 ,  G01N2800/52

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.

公开(公告)号：US20240010988A1

公开(公告)日：2024-01-11

申请号：US18449625

申请日：2023-08-14

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER ,  Xiaomeng HU

IPC: C12N5/071 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  A61K35/39 ,  A61P3/10

CPC classification number: C12N5/0676 ,  C12N9/22 ,  C12N15/111 ,  C12N15/907 ,  A61K35/39 ,  A61P3/10 ,  C12N2510/00 ,  C12N2527/00 ,  C12N2310/20

Abstract: Provided are engineered cells, such as engineered primary cells, containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered primary cells are hypoimmunogenic cells.

公开(公告)号：US20230293593A1

公开(公告)日：2023-09-21

申请号：US17907084

申请日：2021-03-25

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER ,  Rebeca RAMOS-ZAYAS

IPC: A61K35/30 ,  A61P25/28 ,  C12N5/0793 ,  C12N5/079 ,  A61P25/16

CPC classification number: A61K35/30 ,  A61P25/16 ,  A61P25/28 ,  C12N5/0619 ,  C12N5/0622 ,  C12N2506/45

Abstract: Disclosed herein are cells including neural cells that evade immune recognition such as microglial response and related methods of their use and generation. In some embodiments, the cells disclosed herein have reduced levels or activities of MHC I and/ or MHC II human leukocyte antigens, and in some instances, exogenously express CD47. In some embodiments, the cells are derived from pluripotent stem cells that evade immune recognition by a recipient subject.

公开(公告)号：US20230174935A1

公开(公告)日：2023-06-08

申请号：US17997103

申请日：2021-04-27

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER

IPC: C12N5/0783 ,  C07K14/705 ,  A61P37/02

CPC classification number: C12N5/0636 ,  A61P37/02 ,  C07K14/705 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2506/03

Abstract: Disclosed herein are methods of treating a disorder in a patient by administering immune evading cells. In some embodiments, the patient receives more than one administration of such cells. In some embodiments, the cells disclosed herein have reduced levels or activities of MHC I and/or MHC II human leukocyte antigens. In some embodiments, the cells are derived from primary T cells or pluripotent stem cells that evade immune recognition. In some embodiments, the cells comprise a chimeric antigen receptor.